Medications for Diabetic Retinopathy
9 results
Ahzantive (aflibercept-mrbb)
(aflibercept-mrbb)Valorum Biologics Inc
Usage: AHZANTIVE is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Beovu (brolucizumab)
(brolucizumab)Novartis Pharmaceuticals Corporation
Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
Cimerli (ranibizumab-eqrn)
(ranibizumab-eqrn)Coherus BioSciences Inc
Usage: CIMERLI is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
Eylea hd (aflibercept)
(aflibercept)Regeneron Pharmaceuticals, Inc
Usage: EYLEA HD is indicated for treating neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
Iluvien (fluocinolone acetonide)
(fluocinolone acetonide)Alimera Sciences, Inc.
Usage: ILUVIEN® is indicated for treating diabetic macular edema (DME) in patients previously treated with corticosteroids without significant intraocular pressure increase, and for chronic non-infectious uveitis affecting the posterior segment of the eye.
Lucentis (ranibizumab)
(RANIBIZUMAB)Genentech, Inc.
Usage: LUCENTIS is indicated for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
Ozurdex (dexamethasone)
(dexamethasone)Allergan, Inc.
Usage: OZURDEX (dexamethasone intravitreal implant) is indicated for treating macular edema following branch and central retinal vein occlusion, non-infectious uveitis of the posterior segment, and diabetic macular edema.
Susvimo (ranibizumab)
(Ranibizumab)Genentech, Inc.
Usage: SUSVIMO (ranibizumab injection) is indicated for treating Neovascular (wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.
Vabysmo (faricimab)
(Faricimab)Genentech, Inc.
Usage: VABYSMO is indicated for treating patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It works as a VEGF and angiopoietin 2 (Ang-2) inhibitor.